BioVersys AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.bioversys.com
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 35
- Registration Number
- NCT05685615
- Locations
- ππΊ
University of Debrecen Clinical Center, Debrecen, Hungary
ππΊUniversity Educational Hospital, Miskolc, Hungary
ππΊFejer County St. Gyorgy University Teaching Hospital, Szekesfehervar, Hungary
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 40
- Registration Number
- NCT05684705
- Locations
- π¦πΉ
Medical University of Vienna, Vienna, Austria
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 16
- Registration Number
- NCT05684718
- Locations
- ππΊ
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 16
- Registration Number
- NCT05537090
- Locations
- ππΊ
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
A Study to Assess the Phamacokinetics of BV100 in Participants With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 40
- Registration Number
- NCT05537142
- Locations
- ππΊ
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
Completed
- Conditions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 30
- Registration Number
- NCT05258877
- Locations
- πΏπ¦
TASK Applied Sciences, Cape Town, South Africa
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 48
- Registration Number
- NCT05086107
- Locations
- ππΊ
CRU Hungary Kft., Early Phase Unit, Miskolc, Hungary
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BVL-GSK098 in Healthy Volunteers
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 80
- Registration Number
- NCT04654143
- Locations
- πͺπΈ
CIM Sant Pau, Barcelona, Spain
πͺπΈHospital Universitario de La Princesa, Madrid, Spain
Β© Copyright 2024. All Rights Reserved by MedPath